Takeda R&D chief sells 116K ADS at $18.49

Takeda’s R&D president and director reported a Rule 10b5-1 trust sale of 116,191 ADS at $18.49 each, with substantial direct and indirect holdings remaining.

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD (TAK) reported that Andrew Stewart Plump, its President of R&D and a director, sold 116,191 American Depositary Shares on September 2, 2026 at $18.49 per share through a trust. The trust held 145,465 ADS after the sale, and he also reported 766,569 ADS held directly. The sale was made under a Rule 10b5-1 trading plan adopted on May 15, 2026.

Insider Trade Summary 10b5-1

Net Seller: 116,191 shares

Net Sell 2 txns

Insider Plump Andrew Stewart

Role President, R&D

Sold 116,191 shs ($2.15M)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares F1	116,191	$18.49	$2.15M
holding	American Depositary Shares	--	--	--

Holdings After Transaction: American Depositary Shares — 145,465 shares (Indirect, By Trust); American Depositary Shares — 766,569 shares (Direct)

Footnotes (1)

1. F1. The sales reported herein were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026.

Key Figures

Shares sold: 116,191 American Depositary Shares Sale price per ADS: $18.49 per share Indirect holdings after sale: 145,465 American Depositary Shares +2 more

5 metrics

Shares sold 116,191 American Depositary Shares Sale on September 2, 2026 by a trust associated with Andrew Stewart Plump

Sale price per ADS $18.49 per share Price for the 116,191 ADS sold on September 2, 2026

Indirect holdings after sale 145,465 American Depositary Shares Trust position reported following the September 2, 2026 sale

Direct holdings 766,569 American Depositary Shares Direct ownership position reported as of September 2, 2026

Rule 10b5-1 plan adoption date May 15, 2026 Date on which the trading plan governing the reported sales was adopted

Key Terms

American Depositary Shares, Rule 10b5-1 plan, By Trust

3 terms

American Depositary Shares financial

"American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Rule 10b5-1 plan regulatory

"The sales reported herein were effected pursuant to a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

By Trust financial

"By Trust"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Takeda (TAK) report for Andrew Stewart Plump?

Takeda reported that Andrew Stewart Plump sold 116,191 American Depositary Shares on September 2, 2026 through a trust at $18.49 per share, under a pre-established Rule 10b5-1 trading plan adopted on May 15, 2026.

Was the Takeda (TAK) insider sale by Andrew Stewart Plump under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 plan that Andrew Stewart Plump adopted on May 15, 2026, indicating the trades were pre-arranged rather than discretionary at the time of execution.

How many Takeda (TAK) ADS did Andrew Stewart Plump sell and at what price?

He sold 116,191 American Depositary Shares of Takeda on September 2, 2026 at a reported price of $18.49 per share, in an open-market or private sale executed through a trust.

What are Andrew Stewart Plump’s remaining indirect Takeda (TAK) holdings after the reported sale?

After the reported sale, the trust associated with Andrew Stewart Plump held 145,465 American Depositary Shares of Takeda, according to the filing’s post-transaction ownership figure for the indirect holding.

What direct holdings of Takeda (TAK) does Andrew Stewart Plump report?

In addition to the trust position, Andrew Stewart Plump reported a separate direct holding of 766,569 American Depositary Shares of Takeda as of September 2, 2026, listed as a direct ownership entry.

What is Andrew Stewart Plump’s role at Takeda (TAK) in this Form 4?

Andrew Stewart Plump is identified as both a director and an officer of Takeda, with the officer title President, R&D, making him a senior executive reporting insider equity transactions in the company’s securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 09:49 PM EDT Accepted by SEC EDGAR 09/03/2026 - 09:49 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plump Andrew Stewart

(Last) (First) (Middle)

300 MASSACHUSETTS AVE.

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	09/02/2026		S(1)		116,191	D	$18.49	145,465	I	By Trust
American Depositary Shares								766,569	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported herein were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026.

Remarks:

	/s/ Kate Huleatt, by power of attorney, for Andrew Plump	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)